TORONTO, Sept. 1 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, although interspinous process decompression devices will continue to be used in a narrow set of indications over the next five years in Europe, the market will grow at a much lower rate than previously expected. With a compound annual growth rate of 1.2%, this is low compared to the nonfusion market as a whole which is growing on average at 10%.
A form of dynamic stabilization – interspinous process decompression device procedures were the most commonly performed nonfusion surgery in Europe in 2009, accounting for nearly 40% of all spinal nonfusion procedures. Rapid adoption in the past was due in large part to the ease-of-use of the devices, resulting in surgeons implanting them for the treatment of broad indications. Surgeon use of these devices for inappropriate indications, however, resulted in many cases of device failure, which then led to a high volume of revision surgeries. As a result, reimbursement approvals for these devices are becoming stricter and are only granted when used in appropriate indications. Slowing in the number interspinous process decompression device procedures will result in decreased surgeon uptake of popular interspinous process decompression devices, including Medtronic Spinal & Biologic's X-STOP and DIAM, Paradigm Spine's coflex and Zimmer Spine's Wallis.
"Surgeons are losing their initial enthusiasm about the technology, which is attributed to doubts about how effective interspinous process decompression devices are in treating pathological conditions of the spine," says Andrew Lee, Analyst at MRG. "Payors in the UK and Italy are placing pressure on hospitals to reduce the use of interspinous process decompression devices by narrowing the indications for which the devices are reimbursed. Furthermore, poor